<DOC>
	<DOCNO>NCT00759941</DOCNO>
	<brief_summary>The purpose study assess efficacy add Azopt dose three time day Xalatan compare add placebo Xalatan patient elevate intraocular pressure .</brief_summary>
	<brief_title>A Comparison Azopt Versus Placebo Added Xalatan Patients With Elevated Intraocular Pressure ( IOP ) Prostaglandin</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Brinzolamide</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Unilateral bilateral primary open angle glaucoma , ocular hypertension pseudoexfoliation syndrome . Intraocular pressure great 18 mmHg ( mean diurnal ) less 32 mmHg . Other protocoldefined inclusion criterion apply . Exclusion : Previous intraocular surgery , except uncomplicated clear cornea phacoemulsification argon laser trabeculoplasty . Argon laser trabeculoplasty phacoemulsification within last 3 month . Central corneal thickness outside 500 600 ( inclusive ) micron range measure ultrasonic pachymetry . Ocular periocular inflammation within 3 month prior study ( except blepharitis relate seasonal allergic conjunctivitis ) . History uveitis previous intraocular inflammation ( postoperatively ) . Hypersensitivity sulfa , benzalkonium chloride . History use steroid 1 week within 3 month screen likely need corticosteroid study ( except inhale , nasal topical nonocular ) . Other protocoldefined exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Glaucoma</keyword>
</DOC>